Gerald I. Shulman, M.D., Ph.D., has received a Harrington Scholar-Innovator award from The Harrington Discovery Institute for his work on an oral pill that reversed type 2 diabetes and liver disease in rats. The award provides up to $100,000 over two years—with the possibility of receiving up to $700,000.
As part of the award, Shulman will have the opportunity to work with drug development professionals to bring the new drug, controlled-release mitochondrial protonophore, to market.
About 9.3 percent of the U.S. population suffers from diabetes, according to the Centers for Disease Control and Prevention.